Sage Therapeutics is rated a Strong Buy due to its undervaluation, trading below cash holdings, and potential in its drug pipeline, especially Zuranolone. Biogen's $7.22 per share buyout offer signals ...
Biogen to drive end-to-end development and commercialization of ThecaFlex DRx™, an investigational implantable device for intrathecal delivery of antisense oligonucleotides (ASOs) ThecaFlex DRx™ has ...
Venture investors are adopting a more aggressive mindset heading into 2026, while Merck, Moderna and Summit are all approaching crucial trial readouts.
December 25, 2025, 8:37 PM ESTHealth Care November 30, 2025, 6:53 PM ESTTechnology November 24, 2025, 2:02 PM ESTHealth Care November 19, 2025, 9:57 AM ESTHealth Care November 13, 2025, 4:05 PM ...
For decades, Biogen has built a legacy in neuroscience — having brought to market drugs that have changed lives for multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, and more. But ...
Please provide your email address to receive an email when new articles are posted on . Biogen Inc. and Neomorph Inc. have announced a partnership geared toward research and development of molecular ...
Biogen Inc. (NASDAQ:BIIB) is one of the top 10 medical AI companies to buy according to analysts. On July 14, UBS reiterated a ‘Neutral’ rating on the stock and raised the price target to $130 from ...
US biotech Biogen (Nasdaq: BIIB) said the European Commission on January 12, 2026 granted marketing authorization for a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results